[Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer].
The patients were a 59-year-old man and 68-year-old man with previously-treated small cell lung cancer (extensive disease). Amrubicin (40 mg/m(2) and 45 mg/m(2)) was administered for 3 days after brain irradiation. Severe neutropenia continued for nine days from day 8 following administration. Although both patients had an infection, it improved by granulocyte-colony stimulating factor (G-CSF), and antibiotics, plus a blood transfusion. Particular attention for severe myelosuppression should be given to amrubicin therapy with previously-treated small cell lung cancer. However, a detailed blood test in course 1 and early administration of drugs such as G-CSF make this therapy feasible. In addition, to control the condition of patients, repeated administration of amrubicin with dose reduction is recommended.
Suzuki
Hidekazu
H
Dept. of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan.
Sasada
Shinji
S
Matsuda
Yoshinobu
Y
Otani
Yasushi
Y
Morishita
Naoko
N
Kobayashi
Masashi
M
Okamoto
Norio
N
Hirashima
Tomonori
T
Matsui
Kaoru
K
Kawase
Ichiro
I
D000368:Aged; D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced*; D013997:Time Factors
D018943:Anthracyclines; C055866:amrubicin